ClinicalTrials.gg
Sign In
CompletedNCT06062771Updated Oct 2, 2023

Efficacy and Safety of the Use of Ophthalmic Viscosurgical Devices (OVD) FIDIAL PLUS vs IAL®-F During Cataract Surgery

An interventional study of FIDIAL PLUS and IAL®-F in Cataract, sponsored by Fidia Farmaceutici s.p.a.. Completed at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-10-02.

Sponsored by Fidia Farmaceutici s.p.a. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jul 2022, registered Jun 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Prospective, single-center, randomized, controlled, paired-eye, single-masked clinical investigation to compare the efficacy and safety of FIDIAL PLUS (bacterial derived 1.8% sodium hyaluronate OVD) and IAL®-F (comparable animal derived 1.8% sodium hyaluronate OVD) while used during phacoemulsification cataract surgery.

Read the detailed description

Viscoelastics, also referred to as OVDs (ophthalmic viscosurgical devices), are viscous substances that are routinely used in cataract surgery. The most basic benefit of OVD use in ophthalmic surgery is maintaining the anterior chamber during surgical maneuvers. One of the main aspects in OVD use remains the protection of intraocular structures and in particular of corneal endothelium cells (CECs) during cataract surgery.

02

Conditions studied

  • Cataract

Browse trials for

Keywords

  • Ophthalmic Viscosurgical Devices
  • Corneal endothelium cells
  • Cataract Surgery
  • Hyaluronic acid
03

In context

Cataract

1,726 studies on the registry are indexed under Cataract; 230 are open to participants now.

This study's enrollment of 50 is below the median of 80 across 1,171 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Fidia Farmaceutici s.p.a. is the lead sponsor of 32 studies on the registry; 8 are open to participants now.

Browse Fidia Farmaceutici s.p.a. studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject able to comprehend the full nature and the purpose of the study;
  2. Subjects able to cooperate with the Investigator and to comply with the requirements of the entire study;
  3. Subject provided written informed consent to participate in the study obtained according to Good Clinical Practice (GCP);
  4. Females of childbearing potential (i.e., not permanently sterilised - post hysterectomy or tubal ligation status - or not postmenopausal) must have a negative urine pregnancy test result at Screening and surgery days and must use an appropriate method of contraception for at least 30 days before inclusion in the study and during the whole study period, according to the definition in ICH M3 Guideline.

The following criteria apply to both eyes:

  1. Nuclear cataract with visual acuity between 20/200 (logmar 1.0) and 20/32 (logmar 0.2);
  2. Intraocular pressure (IOP) between 14 and 21 mmHg (Goldmann tonometer);
  3. Previous refraction between -5 and +3 diopters in spherical equivalent;
  4. Corneas perfectly transparent without leukoma or other corneal pathology.

Exclusion criteria

Exclusion Criteria:

  1. Any acute, chronic or uncontrolled disease as severe heart failure, recent cardiovascular event, respiratory failure, severe hepatic or renal disease, poorly controlled diabetes mellitus, active severe autoimmune disease, active malignancy etc. that in the opinion of the Investigator, would increase the risk of operation or affect the outcome of the study;
  2. Epilepsy and any other condition that would prevent cooperation during surgery, including head tremor, deafness, neck or back problems, restless legs syndrome, claustrophobia etc.;
  3. Have a history of allergic/hypersensitivity reaction to sodium hyaluronate (NaHA);
  4. Participation in another clinical trial within the past 30 days;

The following criteria apply both eyes:

  1. Corneal endothelium cell density less than 1800 cells/mm square;
  2. Pseudoexfoliation syndrome (PEX) or suspected zonular compromise of any origin;
  3. Corneal angle narrow or/and glaucoma;
  4. Anterior segment pathology likely to increase the risk of an adverse outcome for phacoemulsification cataract surgery (e.g., pseudoexfoliation syndrome, synechiae, iris atrophy, inadequate dilation, shallow anterior chamber, traumatic cataract, lens subluxation etc.);
  5. Any corneal irregularity or leukoma (as assessed by slit lamp and specular microscope pachymetry);
  6. Complicated cataracts;
  7. Subjects requiring implantation of toric lenses;
  8. Proliferative retinopathy, macular degeneration or oedema of any origin. Other ocular pathology that may compromise vision despite successful cataract surgery;
  9. Signs of ocular or systemic infection and/or inflammation;
  10. Previous intraocular surgery, refractive surgery or severe ocular trauma.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    FIDIAL PLUS

    Solution of NaHA 20 mg/1.1 ml pre-filled syringe for intraocular use. 1.8% solution of sodium hyaluronate that is derived from a bacterial fermentation (not of animal origin).

    Device: FIDIAL PLUS

  • Active comparator
    IAL®-F

    Solution of NaHA 20 mg/1.1 ml pre-filled syringe for intraocular use. Animal derived 1.8% sodium hyaluronate OVD.

    Device: IAL®-F

Interventions

  • DeviceFIDIAL PLUS

    1.8% solution of sodium hyaluronate that is derived from a bacterial fermentation (not of animal origin).

  • DeviceIAL®-F

    Animal derived 1.8% sodium hyaluronate equivalent to FIDIAL PLUS

06

What researchers measure

Primary outcomes

  1. Change of corneal endothelium cell density after phacoemulsification cataract surgery with use of two different OVD (Ophthalmic Viscosurgical Devices)

    This outcome will be calculated as percentage of corneal endothelial cells loss at day 28 (T3/T6) when compared with baseline (T0). This will be assessed as a paired t-test comparing the mean percentage change of FIDIAL PLUS against the mean percentage change from baseline of IAL®-F at Day 28. Corneal endothelial cell density will be measured by non-contact specular microscopy.

    Time frame: 28 days per eye

Secondary outcomes

  1. Incidence of a significant (≥30 mmHg) rise in IOP (Intraocular pressure) during study duration

    This will be assessed using McNemar's test to assess the difference in proportion of eyes with a significant rise in IOP during the investigation to the proportion of eyes without a significant rise in IOP during the investigation. IOP will be measured with Goldmann tonometer and expressed in millimeters of mercury (mmHg).

    Time frame: 28 days per eye

  2. Incidence of ocular Treatment Emergent Adverse Events (TEAEs)

    TEAEs are AE reported from the time of the first application of the medical device (MD). TEAEs will be recorded and reported on the case report form (CRF). They will be tabulated by System Organ Class (SOC) and Preferred Term (PT) after medical coding using the Medical Dictionary for Regulatory Activities (MedDRA).

    Time frame: up to 28 days

  3. Incidence of serious ocular Treatment Emergent Adverse Events

    Serious TEAEs are AE reported from the time of the first application of the medical device (MD) that led to: death; to a serious deterioration in health that resulted in a life-threatening illness or injury, or resulted in a permanent impairment of a body structure or a body function, or required in-patient hospitalization or prolongation of existing hospitalization, or resulted in medical or surgical intervention to prevent life threatening illness or injury or permanent impairment to a body structure or a body function; led to foetal distress, foetal death or a congenital abnormality or birth defect.

    Time frame: up to 28 days

  4. Change at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6) of Intraocular pressure (IOP)

    IOP will be measured with Goldmann tonometer at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6) and expressed in millimeters of mercury (mmHg).

    Time frame: Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6)

  5. Central corneal Thickness changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6)

    Central corneal thickness (CCT) will be measured by non-contact specular microscopy at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6)

    Time frame: Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6)

  6. Incidence and grade of anterior chamber inflammation (cells and flare measurement)

    Assessment of anterior chamber inflammation will be performed by slit-lamp biomicroscopy at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6). Slit-lamp examination (SLE) will be performed before and after the instillation of dilating eye drops. Anterior chamber (AC) inflammation will be assessed and graded according to the SUN (Standarization of Uveitis Nomenclature) clinical scoring system. Anterior Chamber Cells grading: Grade 0, cells in field (field size is a 1 mm by 1 mm slit beam) \<1 Grade 0.5+, cells in field 1-5 Grade 1+, cells in field 6-15 Grade 2+, cells in field 16-25 Grade 4+, cells in field \>50 Anterior Chamber Flare Grading: Grade 0, none Grade 1+, Faint Grade 2+, Moderate (iris and lens details clear) Grade 3+, Marked (iris and lens details hazy) Grade 4+, Intense (fibrin or plastic acqueous)

    Time frame: Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6)

  7. Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6) of corneal edema

    Epithelial corneal edema will be assessed with specular microscopy at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6)

    Time frame: Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6)

  8. Change at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6) of corneal endothelial morphology

    It will be assessed by non-contact specular microscopy at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6). Endothelial cell morphology will be analyzed manually or using automated measurements with the retracing method using the manufacturer's built-in image analysis software.

    Time frame: Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6)

  9. Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6) of UDVA (Uncorrected distance visual acuity)

    It will be measured using the Snellen chart at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6). Visual acuity values will be expressed in decimal, fraction or logMAR. All assessments will be performed using standard charts and procedures at specified visual angle, illumination and contrast.

    Time frame: Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6)

  10. Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6) of BCVA (Best corrected distance visual acuity)

    It will be measured using the Snellen chart at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6). Visual acuity values will be expressed in decimal, fraction or logMAR. All assessments will be performed using standard charts and procedures at specified visual angle, illumination and contrast.

    Time frame: Changes at day 1 (T1/T4), day 7 (T2/T5) and day 28 (T3/T6)

07

Study locations

1 site
  • Azienda Ospedaliera Universitaria Integrata di Verona
    Verona, 37126, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06062771
Lead sponsor
Fidia Farmaceutici s.p.a.
Responsible party
Sponsor
First posted
Oct 2, 2023
Start date
Jul 23, 2022
Primary completion
Nov 1, 2022
Completion
Jan 1, 2023
Last update
Oct 2, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cataract →

Other studies from this sponsor

Fidia Farmaceutici s.p.a. →

Start the discussion